News and Trends 4 Jul 2023 Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […] July 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 New drug helps prostate cancer patients Researchers at the Paul Scherrer Institute (PSI) in Switzerland have developed a new drug that could increase the survival chances of patients with metastatic prostate cancer. The drug is now being tested on patients in the PROGNOSTICS project. A research consortium consisting of the PSI, the University Hospital Basel and ETH Zurich is receiving CHF […] July 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2023 Exeliom Biosciences closes €24M financing for lead candidate Exeliom Biosciences has completed a €24 million ($26 million) Series A to progress the clinical development of its therapeutic pipeline. This includes several clinical trials of EXL01, a novel immunotherapy with applications in cancer and in infectious diseases. This follows on from the initial closing of €7 million ($7.6 million) in 2018, a first extension […] July 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2023 FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with a new mechanism of action. It […] June 29, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2023 Actimed Therapeutics raises £5M to advance lead program for cancer cachexia Actimed Therapeutics Ltd, a U.K.-based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, has raised more than £5 million ($6.4 million) in an over-subscribed Series A financing round. The investment will support the development of the Actimed pipeline, including S-pindolol benzoate, with preparations […] June 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jun 2023 European Coalition for Access to Comprehensive Genomic Profiling launched The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) along with Exact Sciences, Guardant Health, Illumina, MSD and Novartis, have launched the European Coalition for Access to Comprehensive Genomic Profiling (ECGP), to improve cancer care through increased routine clinical access and reimbursement of Comprehensive Genomic Profiling (CGP) in Europe. CGP is a method of testing tumors that […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Ovarian cancer study finds key genes for potential treatments New study is increasing knowledge of why some women with the most lethal form of ovarian cancer respond much better to treatment than others. Researchers at Imperial College London in the U.K. have confirmed that the tumors of some women with high-grade serious ovarian cancer (HGSOC) contain a type of lymphoid tissue – known as […] June 22, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2023 Nanobody company Attovia Therapeutics launches with $60M Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, have launched Attovia Therapeutics, a company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2023 FDA clears T-Cell receptor natural killer cell therapy for sarcoma Replay, a genome writing company, and The University of Texas MD Anderson Cancer Center (MD Anderson), have announced that the U.S. Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T-cell receptor natural killer (TCR-NK) cell therapy for advanced synovial […] June 21, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Lighting up cancer: FluoGuide announces positive results from head & neck cancer trial FluoGuide A/S, a Danish biotech company, has announced positive interim results from the phase IIa trial of its lead product FG001 in head & neck cancer. FG001 was shown to illuminate tumors in all of the patients. Data show all 12 patients in the first two cohorts, undergoing surgery for head & neck squamous cell […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 FDA puts hold on Arcellx myeloma program following patient death Arcellx, Inc. has received notification from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on its CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). The clinical hold was received on June 16, following a recent patient death. The company said […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 Clearance for anti-tumor bispecific antibody trial TG ImmunoPharma Co., Ltd. (TGI), which focuses on the development of novel immuno-oncology therapies, says the FDA has granted clearance for the clinical trial of TGI-6, its bispecific antibody. TGI-6 targets unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, enabling potent anti-tumor responses. TGI said the antibody demonstrates exceptional anti-tumor activity, favorable safety profiles, and […] June 20, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email